Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
RPTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.89 - $4.29
Previous CloseN/A
Volume283.97K
Average Volume (3M)392.95K
Market Cap
$58.24M
Enterprise Value-$95.17M
Total Cash (Recent Filing)$84.72M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 13, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,510,708
10 Day Avg. Volume685,985
30 Day Avg. Volume392,954
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.89
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.78
Enterprise Value/Ebitda1.05
Forecast
1Y Price Target
$5.00Price Target Upside264.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Repare Therapeutics News
PremiumCompany Announcements
Repare Therapeutics Announces Leadership Changes in 2025
PremiumCompany Announcements
Repare Therapeutics Focuses on Clinical Trials Amid Restructuring---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst's recommendation remains at Buy despite the net losses reported.
Clinical Trials ProgressRPTX reiterated expected timelines for initial clinical readouts from Phase 1 RP-3467 (Polθi) POLAR trial and from Phase 1 RP-1664 (PLK4i) LIONS trial, indicating steady progress in their clinical trials.
Financial StabilityRPTX provided updated guidance on their cash runway, now extended to late-2027, which shows improved financial stability.
Bears Say
Leadership ChangesThe departure of Chief Medical Officer Maria Koehler suggests potential instability in the company's leadership.
Revenue ProjectionsThe company has deprioritized revenue projections for both lunresertib and camonsertib.
Workforce ReductionThe board's formal approval of a 75% workforce reduction indicates significant organizational changes.
---
Ownership Overview
1.68% Insiders
0.20% Mutual Funds
66.74% Other Institutional Investors
30.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPTX FAQ
What was Repare Therapeutics Inc’s price range in the past 12 months?
Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $4.29 in the past 12 months.
What is Repare Therapeutics Inc’s market cap?
Repare Therapeutics Inc’s market cap is $58.24M.
When is Repare Therapeutics Inc’s upcoming earnings report date?
Repare Therapeutics Inc’s upcoming earnings report date is May 13, 2025 which is in 19 days.
How were Repare Therapeutics Inc’s earnings last quarter?
Repare Therapeutics Inc released its earnings results on Mar 03, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.789 by $0.119.
Is Repare Therapeutics Inc overvalued?
According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued.
Does Repare Therapeutics Inc pay dividends?
Repare Therapeutics Inc does not currently pay dividends.
What is Repare Therapeutics Inc’s EPS estimate?
Repare Therapeutics Inc’s EPS estimate is -0.66.
How many shares outstanding does Repare Therapeutics Inc have?
Repare Therapeutics Inc has 42,510,708 shares outstanding.
What happened to Repare Therapeutics Inc’s price movement after its last earnings report?
Repare Therapeutics Inc reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.789. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Repare Therapeutics Inc?
Currently, no hedge funds are holding shares in RPTX
---
Repare Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (264.96% Upside)
$5.00 (264.96% Upside)
Hedge Fund Trend
Decreased
By 509.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.90%
12-Months-Change
Fundamentals
Return on Equity
-46.63%
Trailing 12-Months
Asset Growth
-30.48%
Trailing 12-Months
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
---
RPTX Stock 12 Month Forecast
Average Price Target
$5.00
▲(264.96% Upside)
Technical Analysis
Spero Therapeutics
―
Prelude Therapeutics
―
Shattuck Labs
―
OnKure Therapeutics
―
Xilio Therapeutics
―
Best Analysts Covering RPTX
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-49.96%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -49.96% per trade.
---